Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiotechnology -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (15)	10/4/2000 2:02:48 AM
From: Mike McFarland	Respond to of 16

Olanzapine Treatment of Obsessive-Compulsive Disorder cpa.medical.org Olanzapine Augmentation in Refractory OCD alertpubs.com see Augmentation in Refractory OCD J Clin Psychiatry 1999 Aug;60(8):524-7 Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. Weiss EL, Potenza MN, McDougle CJ, Epperson CN Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000 Jul;61(7):514-7 Koran LM. Ringold AL. Elliott MA. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000 Aug;57(8):794-801 McDougle CJ. Epperson CN. Pelton GH. Wasylink S. Price LH.